Johnson & Johnson Wins FDA Approval for TRUFILL n-BCA in Chronic Subdural Hematoma Treatment

Reuters12-18
Johnson & Johnson Wins FDA Approval for TRUFILL n-BCA in Chronic Subdural Hematoma Treatment

Johnson & Johnson MedTech has received U.S. Food and Drug Administration (FDA) approval for an expanded indication of the TRUFILL n-BCA Liquid Embolic System. The device is now approved for embolization of the middle meningeal artery $(MMA)$ to treat symptomatic subacute and chronic subdural hematoma (cSDH) as an adjunct to surgery. This approval builds upon TRUFILL n-BCA’s established use in neurovascular embolization and addresses a significant unmet need for patients at risk of recurrence or complications from traditional surgical treatments.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: CL49917) on December 18, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment